Twist Bioscience Corp. — Blitz Index 56 (C)
Twist Bioscience scores 56 — a silicon DNA-synthesis platform whose creative destruction (C 12/15) leads, while GAAP profit still lags margin gains.
Confidence: High · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 17 / 25 | FY2025 +20.3%, Q3 FY2026 +23.2%, 14 straight quarters of sequential growth — but no GAAP profit yet caps the score |
| B · Moat | 34 / 60 | Silicon-platform throughput with improving unit economics (margin 36.6% → 52.8%); no user-to-user network effect, and enzymatic entrants cap the ceiling |
| C · Creative destruction | 12 / 15 | Silicon-chip synthesis replaces legacy chemical/column synthesis on speed, scale and unit cost — the strongest C in the batch |
| D · BlitzFailing | −7 | SBC $64.5M (17.1% of FY2025 revenue) plus a $48.8M business-sale gain flattering the FY2025 net loss; OCF was −$47.6M in FY2025 |
Radar axes (0–100): Moat 56.7 · Speed 68 · Creative 80.
Watch item
Gates: G1 ✓ (confirmed) · G2 ✓ (estimate — bar ≈ $4.32B vs DNA-synthesis TAM alone ~3.1× the bar). 9 points below the threshold — first score.
Strengths
- 14 straight quarters of sequential growth through Q3 FY2026, with FY2026 guidance raised to $456–457M
- Gross margin improved monotonically 36.6% → 42.6% → 50.7% → 52.8% — unit synthesis costs collapsing
- Biopharma revenue +49% and genes shipped +56% in Q3 FY2026, with ~2,650 customers
- $300M upsized offering (Aug 2026) funds the push to adjusted EBITDA breakeven in Q4 FY2026
- No borrowings and a single share class — a clean capital and governance structure
Concerns
- Still GAAP-loss-making (FY2025 operating loss −$136.3M); margin gains have not yet become profit
- FY2025 net-loss improvement included a $48.8M gain on a business sale — the underlying loss persists
- SBC of $64.5M is 17.1% of FY2025 revenue — dilution is the largest single cost
- Enzymatic-synthesis entrants plus IDT and GenScript contest the platform's edge
- DNA-synthesis biosecurity screening and export controls, plus a large-customer concentration risk
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (60/B).
Next earnings
TBD · Unconfirmed
Coverage
Twist Bioscience Corp. · Q4 FY2026 due Nov 13, 2026 (expected, unconfirmed) · Score 56 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.